Language selection

Search

Patent 1189069 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1189069
(21) Application Number: 1189069
(54) English Title: PREPARATION OF PROTECTED 3'DEOXYNUCLEOSIDES
(54) French Title: PREPARATION DE 3'-DESOXYNUCLEOSIDES PROTEGES
Status: Term Expired - Post Grant
Bibliographic Data
(51) International Patent Classification (IPC):
  • C7H 19/02 (2006.01)
  • C7H 19/06 (2006.01)
  • C7H 19/16 (2006.01)
  • C7H 21/00 (2006.01)
(72) Inventors :
  • OGILVIE, KELVIN K. (Canada)
(73) Owners :
(71) Applicants :
(74) Agent: LTD STEWART & KOLASHSTEWART & KOLASH, LTD
(74) Associate agent:
(45) Issued: 1985-06-18
(22) Filed Date: 1983-02-22
Availability of licence: Yes
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract


ABSTRACT OF THE DISCLOSURE
3'-deoxynucleosides are prepared from 2',5'-diprotected
ribonucleosides by a process in which the 3'-hydroxy of the
2',5'-diprotected ribonucleoside is replaced with a substituted
thiocarbonyl group, e.g. by reaction with
phenylchlorothionocarbonate, and then reduced e.g. with
tri(n-butyl)tin monohydride, to form the 3'-deoxy compound.


Claims

Note: Claims are shown in the official language in which they were submitted.


THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY
OR PRIVILEGE IS CLAIMEDD ARE DEFINED AS FOLLOWS:
1. A process for preparing a 3'-deoxynucleoside, which
comprises:
reacting a 2',5'-diprotected ribonucleoside having a
3'-hydroxyl group with a thiocarbonyl compound so as to replace
the hydrogen atom of the 3'-hydroxyl with a substituted
thiocarbonyl group;
removing the substituted thiocarbonyl group from the
3'-position of the 2',5'-diprotected,
3'-(substituted-thiocarbonyl) ribonucleoside so prepared by
chemical reduction, to form therefrom a 2',5'-diprotected,
3'-deoxyribonucleoside;
and optionally deprotecting one or both of the 2' and
5'-positions.
2. The process of claim 1 said replacement of the hydrogen
atom of the 3'-hydroxyl is conducted using phenyl chlorothiono-
carbonate.
3. The process of claim 1 wherein said replacement of the
hydrogen atom of the 3'-hydroxyl is conducted using
(thiocarbonyl)diimidazole.
4. The process of claim 1, claim 2 or claim 3 wherein
reduction to the 3'-deoxyribonucleoside is conducted using an
organo-tin compound.

Description

Note: Descriptions are shown in the official language in which they were submitted.


This invention relates to 3'-deoxyribonucleosides and
derivatives thereof. More particularly, it relates to a process
for the conversion of ribonucleosi~es to 3'-deoxyribonucleosides
and their protected derivatives.
One example of a known 3'-deoxyribonucleoside which has
known and proven utility is the pharmaceutical compound
cordycepin which is 3'-deoxyadenosine of formula:
~L
~o~,/ ~I
~1 0~1
However, known synthetic methods for producing such compounds
containing the 3'-deoxyribose ring are complicated, involving a
substantial number of chemical synthetic steps required to be
conducted sequentially.
The chemical conversion of ribonucleosides to
3'-deoxynucleosides has not been easy to accomplish. Procedures
usually involve halogenation of the carbohydrate ring followed
by replacement of halogen with hydrogen. Alternatively, the
desulfurization of thioanhydronucleosides leads to
deoxynucleosides. 3'-deoxynucleosides such as cordycepin are of
considerable interest for their biological activity, but there
is a need for a general procedure for the conversion of
ribonucleosides into protected 3'-deoxynucleosides, both for

preparation of cordycepin and known compounds and for
preparation of novel compounds for investigation.
According to the present invention~ there is provided a
process for preparing a 3'-deoxynucleoside, which comprises:
reacting a 2',5'-diprotected ribonucleoside having a
3'-hydroxyl group with a thiocarbonyl compound so as to replace
the hydrogen atom of the 3'-hydroxyl with a substituted
thiocarbonyl group;
removing the substituted thiocarbonyl group from the
3'-position of the 2',5'-diprotected,
3'-(substituted-thiocarbonyl) ribonucleoside so prepared by
chemical reduction, to form therefrom a 2',5'-diprotected,
3'-deoxyribonucleoside;
and optionally deprotecting one or both of the 2' and
5'-positions.
2',5'-Diprotected ribonucleosides and their processes
of preparation are known. They are described, for example, in
"Tetrahedron Letters" 4775-4778 (1981), and in "Canadian Journal
of Chemistry" 60, 1106-1113 (1982~, both articles by G.H.
Hakimelahi, Z.A. Proba and K.K. Ogilvie. By means of such
processes, one may obtain compounds of general formula
~0~
( I )
~ o.5i 1
in which B represents a purine or pyrimidine group, e.g. uracil
or adenine, R represents a traditional nucleoside blocking group
such as dimethoxytrityl, and Sil represents a silyl or loweralkyl-
-- 3

sllyl group such as t.butyldimethylsilyl. In the present
invention, such products are reacted and reduced at their
3'-position, to proauce 3'-deoxynucleoside derivatives, which
may then be deprotected.
A suitable reagent to react at the 3'-hydroxyl is
phenyl chlorothionocarbonate, which reacts readily with the
2',5'-protected derivatives of formula I, thus:
Ro~ ~o~c.c~
~o ~.S;) ~ o o,s;l
When the base B is N-protected, however, the yield of clesired
product is low~ The resultant product II may then be reduced,
to replacQ the oxy-thiocarbonyl group with hydrogen, thus
producing a 3'-deoxynucleotide. Suitable reducing agents are
tri(n-butyl)tin monohydride in 2,2'-azobis
(2-methylpropionitrile), thus:
k~ (n l3~)3 S~, ~ > ~>~
~O-C-O ~,Sil (~
The silyl protecting group at position 2' is compound III can be
removed by known methods, e.g. reaction with tetrabutylammonium
fluoride (T~AF~. When B représents an N-protec~ed base group,
j - 4 -

e.g. N-benzoyl protected purines and pyrimidines, the
N-protecting groups are substantially unaffected by TBAF.
An alternative reagent to phenyl chlorothionocarbonate
is (thiocarbonyl) diimidazole. This reacts with compounds of
formula I as follows:
Ro o ~ o c~ ~
M - C~
Uo O,S;l 1~ . C - O O,S;~
(1 ~ s
where IM represents imidazole. Compound IV can be reduced
similarly to compound II, e.g. with (n-Bu)3SnH and 2,2'-azobis
(2-methylpropionitrile) to give a compound of formula III
above. This reaction proceeds well with both N-protected and
N-unprotected nucleosides, although in the case of N-benzoyl-
adenosine and N-benzoylguanosine derivatives, the reaction is
relatively slow.
The end products, of formula V:
R~< \,~1 (V )
o~
can be used directly in nucleotide synthesis. They can be

69
completely deprotected by standard procedures, to give 3'-
deoxynucleosides, such as cordycepin, of pharmacological
interest.
The invention is further described in the following
specific examples:
Example l:
1 m.mole of a protected nucleoside of formula I above,
in which R represented dimethoxytrityl DMT and B represented
uracil, was dissolved in 20ml acetonitrile and 6m.mole
4 (dimethylamino)pyridine, and 5m.mole phenyl
chlorothionocarbonate added. After stirring at room temperature
for six hours the solution was diluted with 40ml ethyl acetate.
The organic layer was washed three times with water, dried over
magnesium sulphate, and evaporated to leave the crude product.
The product was purified by silica gel chromatography. Similar
procedures were adopted and pursued with other starting
materials of formula I, but in which B represented adenine,
N-benzoyladenine, N-benzoylcytosine and N-benzoylguanine.
Results are shown in table I below.
Example 2:
1.1 m.mole of protected nucleoside was dissolved in
lOml dimethyl formamide (DMF) and 3 m.mole (thiocarbonyl)
~iimidazole was added. After stirring at room temperature for
times ranging from 1-85 hours, depending on the starting
material the solution was diluted with lOOml ethyl acetate and

50ml water. The organic layer was separated and was shecl with
water (3 x 50 ml), ~ried over MgSO4 and evaporated at reduced
pressure, the residue was purified by silica gel chromatography.
Reactions were generally over in 4 h except when the
starting material was N-ben~oyladenosine and N-benzoylguanine
derivatives ~hich required 85 h and 70 h respeccively. During
this long reaction period, isomerization of the silyl groups
occurred and mixtures of the 2'- and 3'-derivatives were
obtained. These mixtures were only resolved after reduction and
desilylation~ at which point they were readily separated.
The various starting materials, products, and the
results obtalned, according to Examples 1 and 2 are given in the
following Table 1. The compounds so obtained correspond to
general formuLa IV given above.
TABL~ I
Expt.No. Com~ound of Compound OL Reaction Yielcl Melting
formula II formula IV Time (~)Point
PrepareclPrepared (h) (C)
B R B R
1 Uracil DMT 6 6076-78
2 Uracil D~lT 4 5096-78
3 Adenine DMT 6 60 80-83
4 Adenine DMT 4 56 103-105
. . _
N-benzoyl DMT 85 4051-60
adenine
6 N-benzoyl DMT 4 5288-91
cYtosine
.. , . . . _ _ _ . ...
7 N-benzoyl MMT 70 50 42-49
quanine
. .

DMT represents ~imethoxytrityl, ~T represents monomethoxytrityl.
In each compound the silyl group Si is t-butyldimethylsilyl. In
Experiments 5 and 7 mixtures of 2'- and 3'- isomers were
obtained.
~e~
Compounds prepared according to the previous examples
and listed in Table I were reduced, and the 3'-deoxyderivatives
isolated.
In each case, a mixture of 6 m.mole of the compound, lg
of 2,2'-azobis ~2-methylpropionitrile) and 27 m.mole
(n-Bu)3SnH were heated at reflux in toluene for 3-4 hours.
Solvents were removed and products isolated by silica yel
chromatography. In some cases, the product so obtained, of
general formula III was subsequently de-silylated with
tetrabutylammonium fluoride (TBAF) to obtain product of formula
V. The results are given in Table II below.

TABLE II
Expt.No. Compound of Compound of Reaction Yield Melting
formula III formula V Time (~) Point
PreparedPrepared (hours) 1C)
B R B R
.
8 Uracil DMT 3 55 78-80
9 Uracil DMT 1 95 100-102
. . . _
10 Adenine DMT 4 42 69-72
.
11 Adenine DMT 1 93 123-126
12 N-benzoyl ~iT 4 35 35-45
adenine
13 N-benzoyl MMT 1 50111-112
adenine
. . _ _ . _
14 N benzoyl DMT 4 40 96-98
_ cytosine
N-benzoyl DMT 1 90119-122
cYtosine
-
16 N-benzoyl MMT 4 4135-42
a~uanine
17 N-benzoyl MMT 1 40140-141
auanine
In experiments 12 and 16, mixtures of 2'- and 3'- isomers were
obtained. The isomers were readily separable by TLC after
desilylation.
_ g

Representative Drawing

Sorry, the representative drawing for patent document number 1189069 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: Expired (old Act Patent) latest possible expiry date 2003-02-22
Inactive: Expired (old Act Patent) latest possible expiry date 2003-02-22
Inactive: Reversal of expired status 2002-06-19
Grant by Issuance 1985-06-18

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
None
Past Owners on Record
KELVIN K. OGILVIE
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column (Temporarily unavailable). To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Cover Page 1993-06-10 1 13
Abstract 1993-06-10 1 9
Claims 1993-06-10 1 26
Drawings 1993-06-10 1 7
Descriptions 1993-06-10 8 203